Dr. Hommes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Medical Plz
365 A
Los Angeles, CA 90095Phone+1 310-825-1597Fax+1 310-794-9718
Education & Training
- University of Amsterdam Faculty of MedicineClass of 1990
Certifications & Licensure
- CA State Medical License 2011 - 2019
Clinical Trials
- Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease Start of enrollment: 2010 Jun 01
- Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment Start of enrollment: 2014 Feb 01
- OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome Start of enrollment: 2017 Feb 28
Publications & Presentations
PubMed
- 12 citationsArtificial Intelligence for Inflammatory Bowel Diseases (IBD); Accurately Predicting Adverse Outcomes Using Machine Learning.Aria Zand, Zack Stokes, Arjun Sharma, Welmoed K van Deen, Daniel Hommes
Digestive Diseases and Sciences. 2022-10-01 - 6 citationsPatient Experience and Satisfaction with an e-Health Care Management Application for Inflammatory Bowel DiseasesAria Zand, Audrey Nguyen, Courtney Reynolds, Ariela Khandadash, Eric Esrailian
International Journal of Environmental Research and Public Health. 2021-11-09 - 3 citationsHealth outcomes and experiences of direct-to-consumer high-intensity screening using both whole-body magnetic resonance imaging and cardiological examinationDaniel W. Hommes, Derk Klatte, Wilma Otten, M. Beltman, Günter Klass
Plos One. 2020-11-20
Press Mentions
- InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023April 19th, 2023
- DEARhealth Becomes One of the World’s First Companies to Obtain CE-Marking According to New European Union Medical Device Regulation (MDR)June 10th, 2021
- DEARhealth Recruits Senior Executives to Accelerate GrowthMarch 30th, 2021
Other Languages
- Dutch, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: